|
The changes in DM patients' inflammation parameters. |
||||||
| Parameters |
HC |
Metformin (months) |
Rosiglitazone (months) |
|||
|
|
||||||
| 0 |
1 |
2 |
0 |
2 |
||
|
|
||||||
| WBC × 109 |
6.7 ± 0.1 |
7.3 ± 0.3b |
7.4 ± 0.4 |
7.5 ± 0.2 |
7.04 ± 0.5b |
6.8 ± 0.6 |
| PMNLs × 109 |
4.0 ± 0.1 |
4.6 ± 0.3b |
4.7 ± 0.2 |
4.9 ± 0.1 |
4.2 ± 0.4b |
4.4 ± 0.5 |
| PMNL apoptosis (%) |
4.0 ± 0.1 |
12.7 ± 3.4b |
9.5 ± 2.8a, b |
6.5 ± 1.0a |
20.4 ± 4.4b |
7.5 ± 1.9a |
| Monocytes × 109 |
0.36 ± 0.02 |
0.44 ± 0.05b |
0.40 ± 0.04b |
0.39 ± 0.04a |
0.49 ± 0.03b |
0.39 ± 0.01a |
| Fibrinogen (mg/dl) |
304.6 ± 17.6 |
440.1 ± 25.2b |
471.1 ± 28.8b |
415.9 ± 41.2a, b |
400 ± 16.6b |
332.8 ± 8.1a,b |
| Albumin (g/dl) |
4.6 ± 0.05 |
4.53 ± 0.1 |
4.74 ± 0.1 |
4.7 ± 0.04 |
4.5 ± 0.1 |
4.6 ± 0.1 |
| Transferrin (g/dl) |
273.2 ± 10.6 |
274.6 ± 8.4 |
276.7 ± 7.2 |
287.9 ± 7.7 |
264.7 ± 7.6 |
286.2 ± 8.9 |
| CRP (mg/L) |
1.5 ± 0.1 |
8.3 ± 1.6b |
6.6 ± 1.1b |
5.8 ± 1.5a, b |
4.3 ± 0.9b |
1.8 ± 0.2a,b |
|
a P < 0.05, treated DM patients vs. untreated DM patients; b P < 0.05, untreated DM patients vs. HC subjects | ||||||
Farah et al. Cardiovascular Diabetology 2008 7:20 doi:10.1186/1475-2840-7-20 |
||||||